InnovAge Q4 Revenue Beats by 10%, Guides FY27 Revenue to $1.05B-$1.085B
INNV has more than doubled off its 52-week low of $3.686.
Summary
InnovAge reported fiscal Q4 revenue of $261.95M, beating the $238.27M consensus by 10%, driven by higher participant census and capitation revenue. Adjusted EPS was $0.06, though no analyst estimate was available. The company issued fiscal 2027 guidance: revenue of $1.05B-$1.085B, adjusted EBITDA of $105M-$115M, and census of 8,625-8,850 participants. Center-level contribution margin improved to 23% of revenue, up from 15.5% a year ago, reflecting operational leverage. This follows a Q3 marked by litigation-driven losses, so the margin expansion and positive EPS signal a turnaround. The stock trades at 26x forward earnings versus 20x three months ago, suggesting the market is already pricing in improvement. Watch for analyst revisions following the beat and guidance, and any updates on the pending S-3 shelf offering from controlling shareholder TCO Group Holdings.
At the time of this announcement, INNV was trading at $11.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $3.69 to $12.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.